EBRC has been active in clinical trials for over 15 years and continues to be a site that has been involved in landmark studies involving the treatment of age-related macular degeneration, diabetic retinopathy and retinal vein occlusions. EBRC continues to dedicate our time and efforts toward promoting the advancement in retinal research and improving our surgical and medical care for each of our patients.

Our research team carefully evaluates each research study and selects well-designed and safe clinical studies that will not only benefit each of our participating patients, but also aid in the future discovery of treatment for retinal diseases.

Clinical Trials

Active Clinical Trials

Central Retinal or Hemiretinal Vein Occlusion
  • Comino Study is a phase III trial. This Study will Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion(Genentech/Roche)
Symptomatic Epiretinal Membrane
  • Protocol AM with the Diabetic Retinopathy Clinical Research Network. This Study is a Phase III trial Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic Epiretinal Membrane or ERM (DRCR Network)
Diabetic Macular Edema
  • Pagoda Study is a Phase III trial This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab (Genentech/Roche)
  • Rhone X is a Phase III Trial. This Study Evaluates the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema (Genentech/Roche)

Completed Clinical Trials

Age-Related Macular Degeneration
Diabetic Macular Edema
  • VISTA: Phase III, VEGF-Trap injections/laser in subjects for the treatment of diabetic macular edema.
  • IDEAL: Phase II, iCO-007 as monotherapy or in combination with Ranibizumab or laser for the treatment of diabetic macular edema.
  • READ3: Phase III, Ranibizumab for the treatment of diabetic macular edema with high dose.
  • RIDE: Phase III, Ranibizumab injections in subjects with clinically significant macular edema secondary to diabetes.
Diabetic Retinopathy
Retinal Vein Occlusion
Vitreomacular Traction

Complete Patient Forms

Download Form

Referring Physician Form

Download Form